UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other juri ...

BEDMINSTER, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that James J. Ferguson, M.D., Chief Medical Officer of Matinas, will be presenting two abstracts at the ASGCT 27th Annual Meeting being held May 7-11, 2024 in Baltimore highlighting data from ex vivo, in vitro and in vivo studies evaluating the use of ...

BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day ...

BEDMINSTER, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, demonstrated efficacy compared with placebo in treating the pulmonary mucormycosis fungal infections Rhizopus delemar and M. circinelloides f. jenssenii in immunosuppressed ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q4 2023 Earnings Conference Call March 27, 2024 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Development Officer James Ferguson - Chief Medical Officer Keith Kucinski - Chief Financial Officer Conference Call Participants Rei Tan - BTIG Robert LeBoyer - Noble Capital Markets Operator Welcome, everyone, to the Matinas BioPharma 2023 Financial Results Conference Call. Currently ...

Exhibit 99.1 Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasive fungal infections, including invasive aspergillosis Successful in vivo LNC platform studies demonstrating (a) the oral delivery of ...

公司概况 - 公司是一家专注于利用脂质纳米晶（LNC）平台递送技术开发突破性疗法的临床阶段生物制药公司[465] 财务表现 - 2023年和2022年公司的净亏损分别为22,942美元和20,997美元，公司预计在可预见的未来将继续亏损[469] - 2023年公司通过与BioNTech SE和Genentech Inc.的研究合作产生了1,096美元的合同研究收入[470] - 研发支出主要包括产品候选物MAT2203的开发成本，LNC平台的推进成本，以及与CROs等合作的费用[471] - 2023年公司的研发支出为14,489美元，较2022年的16,678美元有所下降，主要是由于临床试验费用和专业咨询费用的减少[472] - 2023年公司的一般和行政支出为10,373美元，较2022年的11,100美元有所下降，主要是由于某些保险费用的降低和与项目相关的咨询费用和设施费用的降低[473] 现金流和资金状况 - 公司截至2023年12月31日的现金、现金等价物和可交易债务证券总额为13,756美元[488] - 2023年公司的经营活动产生的现金流为15,278美元的负数，较2019年的19,156美元的负数有所减少[490] - 2023年和2022年的融资活动中，融资活动净现金流分别为-7和79美元[492] 风险和展望 - 公司预计未来将继续承担重大费用和增加运营亏损，可能需要通过私人和公共股权发行、债务融资、政府或其他第三方资金、合作和许可安排来满足现金需求[493][494][495][496][497] - 公司的财务状况和运营结果可能受到全球供应链中断、全球贸易争端和/或政治不稳定等无法控制的因素的影响[498]

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO Conference Call Participants Julian Harrison - BTIG Operator Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. [Operator ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38022 MATINAS BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware No. 46-3011414 (State or other ...

Matinas BioPharma Holdings, Inc. (NYSE:MTNB) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerry Jabbour - Chief Executive Officer Terry Matkovits - Chief Development Officer Keith Kucinski - Chief Financial Officer Conference Call Participants Julian Harrison – BTIG Operator Welcome to the Matinas BioPharma Second Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management’s ...